Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
Tweet
Share
E-mailGet Alerts OTLK Hot Sheet
Join SI Premium – FREE
Outlook Therapeutics (NASDAQ: OTLK) reported Q3 EPS of ($0.09). Revenue for the quarter came in at $9 thousand.
For earnings history and earnings-related data on Outlook Therapeutics (OTLK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GameStop CEO Cohen buys 1.15M shares
- Adeptus Biotechnologies Corp. (ADPT) PT Raised to $34 at BTIG
- Vicor raises Q3 2026 revenue guidance on new licensing deal
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
